Section

GLP-1

Semaglutide, tirzepatide, retatrutide and the incretin race.

12:30Health and Me
Retatrutide Vs Ozempic: Eli Lilly’s Experimental Drug Delivers More Than Double The Weight Loss
By Maren Holt
Oct 31Big News Network.com
Lilly's retatrutide beats Ozempic on weight loss in trial
By Maren Holt
Oct 31News18
Retatrutide Vs Ozempic: Next-generation Jab Doubles Weight Loss In Trial
By Maren Holt
Oct 30Hindustan Times
The promise and perils of the peptide craze | Hindustan Times
By Maren Holt
Oct 30Biomedicine & pharmacotherapy = Biomedecine & pharmacotherapie
Association of GLP-1 receptor agonist therapy with cardiovascular outcomes in patients with MASLD: A translational study
By Maren Holt
Oct 30Medical News Today
Experimental weight-loss drug retatrutide may help improve sleep apnea
By Maren Holt
Oct 30Woman's World
This Online GLP-1 Program Costs $69 a Month, and the Price Never Goes Up With Your Dose
By Maren Holt
Oct 30Medscape
Retatrutide Tops Ozempic for Weight Loss, A1c in T2D
By Maren Holt
Oct 29Medical Daily
Retatrutide Beat Ozempic on Blood Sugar and Weight in Diabetes Trial, but More Patients Quit Over Side Effects
By Maren Holt
Oct 29Medicina clinica
Activities of daily living and health status benefits of semaglutide in very old patients with heart failure, type 2 diabetes, and obesity: Real-world practice study
By Maren Holt
Oct 29The lancet. Diabetes & endocrinology
Efficacy and safety of oral orforglipron in Japanese participants with obesity disease (ATTAIN-J): a double-blind, randomised, placebo-controlled, parallel-group, phase 3 trial
By Maren Holt
Oct 29The lancet. Diabetes & endocrinology
Oral small-molecule GLP-1 receptor agonist for obesity in people from Japan
By Maren Holt
Oct 29JACC. Advances
Cardiovascular and Cerebrovascular Outcomes Risk Reduction Associated With Semaglutide vs Tirzepatide: Methodological Concerns
By Maren Holt
Oct 29Expert review of clinical pharmacology
From metabolic therapy to addiction care: a clinical pharmacology roadmap for GLP-1 receptor agonists in substance use disorders
By Maren Holt
Oct 29Bioengineer.org
GLP-1 Diabetes Drugs Linked to Greater Thyroid Hormone Sensitivity in Large Study
By Maren Holt
Oct 29BW Healthcare World
Lilly’s Retatrutide Delivers Greater Weight Loss Than Ozempic In Trial
By Maren Holt
Oct 29Voice of Healthcare
Lilly’s Retatrutide Outperforms Ozempic in Weight Loss and Blood Sugar Control Trial
By Maren Holt
Oct 29Ynetnews
Health Ministry warns against illegal peptides marketed for weight loss
By Maren Holt
Oct 29Livemint
Ozempic vs Retatrutide: Eli Lilly claims 'more than double' the weight loss in latest trial — What's next?
By Maren Holt
Oct 28Endocrinologia, diabetes y nutricion
Cutaneous vasculitis associated with subcutaneous semaglutide
By Maren Holt
Oct 28Diabetes, obesity & metabolism
Early Treatment Trajectory and Long-Term Persistence to Semaglutide for Obesity: A Population-Based Cohort Study
By Maren Holt
Oct 28Diabetes research and clinical practice
Semaglutide versus other GLP-1 RAs and cardiovascular risk in obesity-related cancer survivors
By Maren Holt
Oct 28Endocrine
Comparative adverse-event reporting patterns of semaglutide and tirzepatide: a disproportionality analysis of FAERS
By Maren Holt
Oct 28Expert opinion on pharmacotherapy
Switching between semaglutide and tirzepatide in obesity Management: an expert-consensus framework for approximate clinical Efficacy-matched switching doses
By Maren Holt
Oct 28The American Journal of Managed Care
Retatrutide Tops Semaglutide on A1C, Weight in Head-to-Head Trial
By Maren Holt
Oct 28Bioengineer.org
GLP-1 Receptor PET/CT Detects Gastrinomas That SSTR Imaging Misses
By Maren Holt
Oct 28Everyday Health
Retatrutide Helped People With Diabetes Lose Twice as Much Weight as Ozempic, New Trial Shows
By Maren Holt
Oct 28MedCity News
Eli Lilly’s ‘Triple-G’ Drug Tops Ozempic in Head-to-Head Type 2 Diabetes Trial
By Maren Holt
Oct 28Nacionale
Retatrutide vs Ozempic: Lilly’s triple-acting drug doubled weight loss in a head-to-head trial
By Maren Holt
Oct 28USA Today
Retatrutide beats Ozempic on weight loss, blood sugar control, study says
By Maren Holt
Oct 28Quartz
Lilly's retatrutide more than doubled Ozempic weight loss in trial
By Maren Holt
Oct 28Clinical Trials Arena
Lilly’s retatrutide beats Ozempic in head-to-head trial
By Maren Holt
Oct 28New York Post
New weight loss drug proves twice as powerful as Ozempic’s highest dosage
By Maren Holt
Oct 28Reuters
Lilly's retatrutide outshines Ozempic on weight loss, blood sugar control in trial
By Maren Holt
Oct 28BioPharma Dive
Lilly’s ‘triple-G’ drug tops Novo’s Ozempic in diabetes trial
By Maren Holt
Oct 28KFI AM 640
Eli Lilly’s New Drug Shows Double The Weight Loss Of Ozempic In New Study
By Maren Holt
Oct 28Newser
In Head-to-Head Trial, Retatrutide Crushes Ozempic
By Maren Holt
Oct 28STAT
STAT+: Pharmalittle: We’re reading about 340B battles, new results for a Lilly weight loss drug, and more
By Maren Holt
Oct 28STAT
STAT+: Lilly’s triple-G drug beats Ozempic in head-to-head study
By Maren Holt
Oct 28Around Prague
How Lilly's Retatrutide Compared With Ozempic in a Head-to-Head Diabetes Trial
By Maren Holt